Acadia Pharmaceuticals
ACAD
196 hedge funds and large institutions have $2.74B invested in Acadia Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 68 increasing their positions, 69 reducing their positions, and 34 closing their positions.
1.33% more ownership
Funds ownership: 96.63% → 97.96% (+1.3%)
1% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 69
7% less funds holding
Funds holding: 210 → 196 (-14)
24% less capital invested
Capital invested by funds: $3.61B → $2.74B (-$869M)
29% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 34
51% less call options, than puts
Call options by funds: $28.3M | Put options by funds: $57.5M
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$69M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$63.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$54.3M |
| 4 |
HM
HealthCor Management
New York
|
+$38.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$23.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$68.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$40.6M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$29.7M |
| 4 |
FAM
Fred Alger Management
New York
|
-$22.1M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$19.9M |
ACAD Hedge Fund Activity: Q1 2018 in Review
196 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q1 2018, worth a combined $2.74B — down 24% from $3.61B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ACAD and 24 opened new positions — a net loss of 10 holders — while 69 trimmed existing stakes and 68 added.
The largest buyer was OrbiMed, adding an estimated $69M. The largest seller was Waddell & Reed Financial, cutting an estimated $68.7M.
- 196 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q1 2018, down from 210 in Q4 2017.
- Funds reported $2.74B of Acadia Pharmaceuticals stock for Q1 2018, down 24% quarter-over-quarter.
- 24 funds opened new Acadia Pharmaceuticals positions in Q1 2018 and 34 closed out, a net change of -10 holders.
- The largest Acadia Pharmaceuticals buyer in Q1 2018 was OrbiMed, an estimated $69M added.
- The largest Acadia Pharmaceuticals seller in Q1 2018 was Waddell & Reed Financial, an estimated $68.7M sold.
Based on aggregated 13F filings for Q1 2018.